Barinthus Biotherapeutics

NASDAQ: BRNS · Real-Time Price · USD
1.26
0.02 (1.61%)
At close: Aug 18, 2025, 10:57 AM

Barinthus Biotherapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a -9.17M 14.97M n/a n/a 5.37M n/a 334K 468K 6.46M 6.17M 17.06M 15.02M -1K 19K 35K 215K
Cost of Revenue
n/a 1.42M 1.49M 1.47M 1.43M 1.45M 1.47M 1.62M n/a n/a n/a n/a n/a n/a n/a n/a n/a
Gross Profit
n/a 2.9M 13.63M -1.47M -1.43M 3.92M -1.47M -1.29M 468K 6.46M 6.17M 17.06M 15.02M -1K 19K 35K 215K
Operating Income
-20.6M -23.39M -9.38M -18.29M -16.91M -19.99M -16.11M -26.34M -21.48M -26.04M 7.24M 13.23M 654K -16.67M -5.54M -16.84M -6.17M
Interest Income
556K 637K 631K 635K 775K 575.97K 196K 522K 1.59M 1.32M 1.03M 669K 83K n/a n/a n/a 2K
Pretax Income
-19.68M -20.59M -8.13M -16.95M -15.56M -18.11M -14.71M -24.96M -18.74M -23.18M 7.55M 14.77M 1.71M -15.14M -4.58M -15.97M -15.45M
Net Income
-19.65M -20.53M -8.11M -16.93M -15.49M -17.29M -14.07M -23.8M -18.18M -21.19M 8.24M 15.69M 2.6M -15.11M -4.56M -15.93M -15.27M
Selling & General & Admin
12.64M 3.06M 13.42M 5.84M 5.99M 13.73M 961K 13.13M 12.14M 20.31M -10.81M -6.45M 3.66M 9.79M 1.18M 12.37M 1.78M
Research & Development
7.99M 6.22M 10.53M 10.97M 11.12M 5.83M 13.94M 12.98M 8.66M 12.1M 10.47M 8.89M 9.65M 5.67M 3.41M 3.63M 3.65M
Other Expenses
-27K 11.79M 398K 20K 389K 540K 1.21M 559K n/a n/a n/a 553K n/a n/a 0.00 -3K n/a
Operating Expenses
20.6M 25.39M 24.35M 17.32M 15.68M 19.99M 14.9M 26.67M 21.95M 32.4M -347K 3M 13.32M 15.46M 4.6M 16M 5.43M
Interest Expense
13K 12K 17K 12K 12K 7.06K 7K 14K n/a 22.16K n/a 7K 74K 18K n/a n/a 2.65M
Selling & Marketing Expenses
n/a n/a n/a -1.36M n/a 118K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
20.6M 17.66M 24.35M 18.98M 16.91M 26M 14.9M 26.67M 20.8M 32.4M -347K 3M 13.32M 15.46M 4.6M 16M 5.43M
Income Tax Expense
-22K 3K -3K -7K -631K -827K -603K -1.14M -516K -2.02M -674K -915K -863K 32K -7K 12K -65K
Shares Outstanding (Basic)
40.27M 39.35M 39.42M 39.04M 38.77M 38.6M 38.53M 38.41M 38.01M 37.68M 37.25M 37.2M 37.19M n/a 34.84M 24.9M 34.06M
Shares Outstanding (Diluted)
40.27M 39.35M 39.42M 39.04M 38.77M 38.6M 38.53M 38.41M 38.01M 37.68M 38.16M 38.17M 38.35M n/a 34.84M 24.9M 34.06M
EPS (Basic)
-0.49 -0.51 -0.21 -0.43 -0.4 -0.45 -0.37 -0.62 -0.48 -0.56 0.22 0.42 0.07 n/a -0.13 -0.64 -0.45
EPS (Diluted)
-0.49 -0.51 -0.21 -0.43 -0.4 -0.45 -0.37 -0.62 -0.48 -0.56 0.22 0.41 0.07 n/a -0.13 -0.64 -0.45
EBITDA
-17.63M -19.15M -6.64M -15.47M -14.12M -16.67M -13.23M -23.65M -17.52M -21.1M 8.66M 15.77M 2.75M -14.8M -4.49M -15.87M -12.71M
EBIT
-19.67M -20.58M -8.12M -16.94M -15.54M -18.1M -14.71M -24.95M -18.74M -22.28M 7.48M 14.78M 1.78M -15.12M -4.58M -15.97M -12.8M
Depreciation & Amortization
2.03M 1.43M 1.49M 1.47M 1.43M 1.45M 1.47M 1.3M 1.23M 1.18M 1.18M 983.37K 960.47K 321K 84.62K 103.8K 92.32K